Aminoglutethimide, a drug known to block adrenal steroidogenesis and peripheral aromatization of androgens to estrogens, has been found effective in the treatment of breast cancer. The drug has been used in our Institute to treat 71 consecutive metastatic breast cancer patients. Of 67 patients evaluable for response, 9 (13.4 %) have achieved a partial response, 30 (44.7 %) stable disease, and 28 (41.7 %) progression of disease. Four patients were taken off the therapy because of drug-related toxicity.
Get full access to this article
View all access options for this article.
References
1.
CoonsesR.C., DadyP., ParsonsC., McReadyV.R., FordM.T., GazetJ.C., PowlesT.J.: Assessment of response of bone metastases to systemic treatment in patients with breast cancer.Cancer, 52: 610–614, 1983.
2.
OkenM.M., CreechR.M., TormeyD.C., HortonJ., DavisT.E., McFaddenE.T., CarboneP.P.: Toxicity and response criteria of the Eastern Cooperative Oncology Group.Am. J. Oncol., 5: 649–655, 1982.
3.
SantenR.J.: Suppression of estrogens with aminoglutethimide and hydrocortisone (medical adrenalectomy) as treatment of advanced breast carcinoma: A review.Breast Cancer Res. Treat., 1: 183–202, 1981.
4.
SantenR.J., WorgulT.J., SamojlikE., InterranteA., BoucherA.E., LiptonA., HarneyH.A., WhiteD.S., SmartE., CoxC., WellsS.A.: Randomized trial comparing surgical adrenalectomy with aminoglutethimide plus hydrocortisone in women with advanced breast cancer.N. Engl. J. Med., 305: 545–551, 1981.
5.
SmithI.E., HarrisA.L., MorganM., FordH.T., GazetJ.C., HarmerC.L., WhiteH., ParsonC.A., VillardoA., WalshG., McKinnaJ.D.: Tamoxifen versus aminoglutethimide in advanced breast carcinoma: A randomized cross-over trial.Br. Med. J., 283: 1432–1434, 1981.
